Epclusa Pellet
NDC Package 61958-2204-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Epclusa (velpatasvir and sofosbuvir) pellets is a medication a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. This formulation utilizes a pellet delivery system. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-2204 and is authorized under FDA application NDA214187.

Identification & Billing

NDC Package Code
61958-2204-1
Package Description
28 PACKET in 1 CARTON / 1 PELLET in 1 PACKET
Product Code
61958-2204
11-Digit Billing Format
61958220401
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
28 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Epclusa
Non-Proprietary Name
Velpatasvir And Sofosbuvir
Substance Name
Sofosbuvir; Velpatasvir
Dosage Form
Pellet - A small sterile solid mass consisting of a highly purified drug (with or without excipients) made by the formation of granules, or by compression and molding.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Pharmacologic Class
Usage Information
This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice "safer sex" (including the use of latex condoms) to lower the risk of passing the virus to others.

Regulatory & Marketing

Labeler Name
Gilead Sciences, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA214187
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
06-10-2021
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 61958-2204-1 identifies a specific commercial package of 28 packet in 1 carton / 1 pellet in 1 packet of Epclusa, a human prescription drug labeled by Gilead Sciences, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 28 billable units per package. This pellet is formulated for oral use and contains sofosbuvir; velpatasvir as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gilead Sciences, Inc. on June 10, 2021. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice "safer sex" (including the use of latex condoms) to lower the risk of passing the virus to others.

How is this Gilead Sciences, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958220401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 28 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
61958-2204-1
11-Digit CMS (5-4-2)
61958-2204-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.